webinar register page

Webinar: Precision Medicine in Cholangiocarcinoma: How Comprehensive Molecular Profiling Identifies Personalized Treatment Options for Patients
Between 2018 and 2021, several targeted drug therapies achieved FDA approval for use in cholangiocarcinoma based on specific gene alterations identifiable by next-generation sequencing. Comprehensive genetic profiling is now widely supported by US and international guidelines to support therapeutic decision making in this disease.

Notably, ASCO selected the role of molecular profiling in driving progress in GI cancers as the 2021 Advance of the Year in oncology, including biliary tract and gall bladder cancers. As these cancers are represented by biologically different tumor subtypes, next generation sequencing through both tumor-tissue panels and blood-based "liquid biopsy" tests for circulating tumor DNA critically inform oncologists on which genetic alterations may be targetable drivers of individual patients' tumors. This knowledge facilitates the selection of optimal therapies and/or enrollments into specific clinical trials, leading to better outcomes for patients.

In this presentation, Calvin Chao, MD, Sr Vice President of Medical Affairs at Tempus will review a current update of diagnostic and therapeutic advances in cholangiocarcinoma, with a focus on the central role of molecular testing platforms.

Oct 28, 2021 01:00 PM in Mountain Time (US and Canada)

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Cholangiocarcinoma Foundation.